|
Number of participants
|
3934
|
2386
|
1873
|
1982
|
517
|
1544
|
404
|
|
Subtype of breast cancer
|
|
Unclassified
|
1151
|
─
|
691
|
─
|
182
|
278
|
─
|
|
Classified
|
2783
|
─
|
1182
|
─
|
335
|
1266
|
─
|
|
Triple negative (ER–/PR–/HER2–)
|
515 (18.5)
|
─
|
329 (27.8)
|
─
|
21 (6.3)
|
165 (13.0)
|
─
|
|
Luminal-like (ER+ and/or PR+)
|
2056 (73.9)
| |
758 (64.1)
| |
277 (82.7)
|
1021 (80.7)
| |
|
HER2-enriched (ER–/PR–/HER2+)
|
212 (7.6)
|
─
|
95 (8.0)
|
─
|
37 (11.0)
|
80 (6.3)
|
─
|
|
Mean age at reference date, years (SD)
|
47.3 (7.4)
|
47.9 (8.1)
|
48.9 (8.5)
|
48.8 (8.4)
|
51.5 (7.3)
|
44.0 (3.9)
|
43.5 (3.8)
|
|
Menopausal status
|
|
Premenopausal
|
2427 (61.7)
|
1257 (52.7)
|
929 (49.6)
|
927 (46.8)
|
203 (39.3)
|
1295 (83.9)
|
330 (81.7)
|
|
Postmenopausal
|
1507 (38.3)
|
1129 (47.3)
|
944 (50.4)
|
1055 (53.2)
|
314 (60.7)
|
249 (16.1)
|
74 (18.3)
|
|
Never used MHT
|
650 (43.1)
|
466 (41.3)
|
409 (43.3)
|
430 (40.8)
|
107 (34.1)
|
134 (53.8)
|
36 (48.7)
|
|
Ever used MHT
|
857 (56.9)
|
663 (58.7)
|
535 (56.7)
|
625 (59.2)
|
207 (65.9)
|
115 (46.2)
|
38 (51.3)
|
|
Race
|
|
White
|
2849 (72.4)
|
1503 (63.0)
|
1056 (56.4)
|
1134 (57.2)
|
435 (84.1)
|
1358 (88.0)
|
369 (91.3)
|
|
African-American
|
1085 (27.6)
|
883 (37.0)
|
817 (43.6)
|
848 (42.8)
|
82 (15.9)
|
186 (12.0)
|
35 (8.7)
|
|
BMI at age 18 years, kg/m2
|
|
< 20.0
|
1921 (48.8)
|
1110 (46.5)
|
882 (47.1)
|
906 (45.7)
|
286 (55.3)
|
753 (48.8)
|
204 (50.5)
|
|
20.0–24.9
|
1740 (44.2)
|
1061 (44.5)
|
848 (45.3)
|
893 (45.1)
|
207 (40.0)
|
685 (44.4)
|
168 (41.6)
|
|
≥ 25.0
|
273 (6.9)
|
215 (9.0)
|
143 (7.6)
|
183 (9.2)
|
24 (4.6)
|
106 (6.9)
|
32 (7.9)
|
|
Recent BMI, kg/m2
|
|
< 25.0
|
2292 (58.3)
|
1271 (53.3)
|
985 (52.6)
|
1003 (50.6)
|
345 (66.7)
|
962 (62.3)
|
268 (66.3)
|
|
25.0–29.9
|
968 (24.6)
|
652 (27.3)
|
511 (27.3)
|
570 (28.8)
|
115 (22.2)
|
342 (22.2)
|
82 (20.3)
|
|
≥ 30.0
|
674 (17.1)
|
463 (19.4)
|
377 (20.1)
|
409 (20.6)
|
57 (11.0)
|
240 (15.5)
|
54 (13.4)
|
